These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16531261)

  • 41. Children with myelodysplastic syndrome (MDS) and increasing mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapy.
    Bader P; Niemeyer C; Willasch A; Kreyenberg H; Strahm B; Kremens B; Gruhn B; Dilloo D; Vormoor J; Lang P; Niethammer D; Klingebiel T; Beck JF
    Br J Haematol; 2005 Mar; 128(5):649-58. PubMed ID: 15725087
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes.
    Knipp S; Hildebrand B; Kündgen A; Giagounidis A; Kobbe G; Haas R; Aul C; Gattermann N; Germing U
    Cancer; 2007 Jul; 110(2):345-52. PubMed ID: 17559141
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity.
    Hoppe BS; Moskowitz CH; Filippa DA; Moskowitz CS; Kewalramani T; Zelenetz AD; Yahalom J
    J Clin Oncol; 2008 Apr; 26(11):1858-64. PubMed ID: 18332466
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia.
    Ferrara F; Mele G; Palmieri S; Pedata M; Copia C; Riccardi C; Izzo T; Criscuolo C; Musto P
    Hematol Oncol; 2009 Dec; 27(4):198-202. PubMed ID: 19475701
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is there a plateau in the survival curve after autologous transplantation in patients with intermediate and high-risk acute myeloid leukemia? A 20-year single institution experience.
    Ganguly S; Singh J; Divine CL; Deauna-Limayo D; Bodensteiner DC; Lewis JL; Curran K; Skikne BS
    Leuk Res; 2007 Sep; 31(9):1253-7. PubMed ID: 17320953
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Intensive chemotherapy in myelodysplastic syndromes].
    Dombret H
    Pathol Biol (Paris); 1997 Oct; 45(8):627-35. PubMed ID: 9569928
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acute myeloid leukemia and the position of autologous stem cell transplantation.
    Breems DA; Löwenberg B
    Semin Hematol; 2007 Oct; 44(4):259-66. PubMed ID: 17961725
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.
    Tsukimoto I; Tawa A; Horibe K; Tabuchi K; Kigasawa H; Tsuchida M; Yabe H; Nakayama H; Kudo K; Kobayashi R; Hamamoto K; Imaizumi M; Morimoto A; Tsuchiya S; Hanada R
    J Clin Oncol; 2009 Aug; 27(24):4007-13. PubMed ID: 19620491
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.
    Yanada M; Huang X; Garcia-Manero G; O'brien S; Ravandi F; Borthakur G; Faderl S; Issa JP; Kantarjian H; Estey E
    Br J Haematol; 2007 Aug; 138(4):555-7. PubMed ID: 17593249
    [No Abstract]   [Full Text] [Related]  

  • 50. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission.
    Schmid C; Schleuning M; Hentrich M; Markl GE; Gerbitz A; Tischer J; Ledderose G; Oruzio D; Hiddemann W; Kolb HJ
    Bone Marrow Transplant; 2008 Apr; 41(8):721-7. PubMed ID: 18176613
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantation.
    Graef T; Vaupel M; Fenk R; Ruf L; Zohren F; Germing U; Haas R; Kobbe G
    Hematol Oncol; 2007 Dec; 25(4):170-7. PubMed ID: 17579887
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term survival in acute leukemia. Twenty-two adult patients surviving for over five years.
    Evensen SA; Stavem P
    Acta Med Scand; 1986; 219(1):79-83. PubMed ID: 3456695
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
    Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
    Lin Q; Dong M; Wang QM; Wen JY; Wu XY
    Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia.
    Horwitz ME
    Curr Opin Oncol; 2011 Mar; 23(2):197-202. PubMed ID: 21252669
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
    Mi YC; Xue YP; Yu WJ; Liu SH; Zhao YZ; Meng QX; Bian SG; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):705-9. PubMed ID: 16620570
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias.
    Morgan MA; Reuter CW
    Ann Hematol; 2006 Mar; 85(3):139-63. PubMed ID: 16391911
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia.
    Cho BS; Kim HJ; Lee S; Eom KS; Min WS; Lee JW; Kim CC
    Eur J Haematol; 2007 Aug; 79(2):170-3. PubMed ID: 17608710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.